This study aimed to evaluate the use of serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in the diagnosis of Alzheimer’s disease (AD) and the differential diagnosis between AD and mild cognitive impairment (MCI). This evidence concerns the gene GFAP and Alzheimer disease.